<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30184033</article-id><article-id pub-id-type="pmc">6122764</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0078</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Thrombocytopenia After Transcatheter Valve-in-Valve Implantation:
Prognostic Marker or Mere Finding?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>de Souza</surname><given-names>Renato C.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Paim</surname><given-names>Leonardo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Viotto</surname><given-names>Guilherme</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Aprigio</surname><given-names>Joaquim</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Ara&#x000fa;jo</surname><given-names>Lucas L.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Ribeiro</surname><given-names>Henrique</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Sampaio</surname><given-names>Roney O.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Tarasoutchi</surname><given-names>Flavio</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Pomerantzeff</surname><given-names>Pablo M. A.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Palma</surname><given-names>Jos&#x000e9; Hon&#x000f3;rio</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Jatene</surname><given-names>Fabio B.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><aff id="aff1">
<label>1</label> Cardiovascular Surgery Division, Instituto do
Cora&#x000e7;&#x000e3;o do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina
da Universidade de S&#x000e3;o Paulo (InCor-HCFMUSP), S&#x000e3;o Paulo, SP,
Brazil.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Leonardo Paim Nicolau da Costa, Av. Dr.
En&#x000e9;as de Carvalho Aguiar, 44 - S&#x000e3;o Paulo, SP, Brazil, Zip code:
05403-900. E-mail: <email>drleonardopaim@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jul-Aug</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2018</year></pub-date><volume>33</volume><issue>4</issue><fpage>362</fpage><lpage>370</lpage><history><date date-type="received"><day>12</day><month>3</month><year>2018</year></date><date date-type="accepted"><day>27</day><month>4</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To analyze the behavior of platelets after transcatheter valve-in-valve
implantation for the treatment of degenerated bioprosthesis and how they
correlate with adverse events upon follow-up.</p></sec><sec><title>Methods</title><p>Retrospective analysis of 28 patients who received a valve-in-valve implant,
5 in aortic, 18 in mitral and 5 in tricuspid positions. Data were compared
with 74 patients submitted to conventional redo valvular replacements during
the same period, and both groups' platelet curves were analyzed. Statistical
analysis was conducted using the IBM SPSS Statistics(r) 20 for Windows.</p></sec><sec><title>Results</title><p>All patients in the valve-in-valve group developed thrombocytopenia, 25%
presenting mild (&#x0003c;150.000/&#x000b5;L), 54% moderate
(&#x0003c;100.000/&#x000b5;L) and 21% severe (&#x0003c;50.000/&#x000b5;L)
thrombocytopenia. The platelet nadir was on the 4<sup>th</sup> postoperative
day for aortic ViV, 2<sup>nd</sup> for mitral and 3<sup>rd</sup> for
tricuspid patients, with the majority of patients recovering regular
platelet count. However, the aortic subgroup comparison between
valve-in-valve and conventional surgery showed a statistically significant
difference from the 7<sup>th</sup> day onwards, where valve-in-valve
patients had more severe and longer lasting thrombocytopenia. This, however,
did not translate into a higher postoperative risk. In our study population,
postoperative thrombocytopenia did not correlate with greater occurrence of
adverse outcomes and only normal preoperative platelet count could
significantly predict a postoperative drop &#x0003e;50%.</p></sec><sec><title>Conclusion</title><p>Although thrombocytopenia is an extremely common finding after valve-in-valve
procedures, the degree of platelet count drop did not correlate with greater
incidence of postoperative adverse outcomes in our study population.</p></sec></abstract><kwd-group><kwd>Thrombocytopenia</kwd><kwd>Transcatheter Aortic Valve Replacement</kwd><kwd>Heart Valve Prosthesis Implantation</kwd><kwd>Heart Valves/Surgery</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="42%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="42%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="2" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">AKI</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Acute
kidney injury</td><td rowspan="8" align="left" valign="top" colspan="1">&#x000a0;</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">MODS</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Multiple
Organ Dysfunction Score</td></tr><tr><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">BAV</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Balloon
aortic valvuloplasties</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">PCI</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">=
Percutaneous coronary interventions</td></tr><tr><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary
artery bypass grafting</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">SAVR</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Surgical
aortic valve replacement</td></tr><tr><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">=
Cardiopulmonary bypass</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">SOFA</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Sequential
organ failure assessment</td></tr><tr><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">HIT</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">=
Heparin-induced thrombocytopenia</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">TAVR</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">=
Transcatheter aortic valve replacement</td></tr><tr><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">IABP</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">=
Intra-aortic balloon pumps</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">VARC-2</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Valve
Academic Research Consortium</td></tr><tr><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICU</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intensive
care unit</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">ViV</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">=
Valve-in-valve</td></tr><tr><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">LODS</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Logistic
Organ Dysfunction Score</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" valign="top" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Thrombocytopenia is defined as an absolute platelet count &#x0003c;150.000/&#x000b5;L or a
decrement greater than 50% from baseline value<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. This is a common finding in critically ill
patients classically associated with poor prognosis, prolonged hospital stay, higher
risk and, ultimately, reduced survival<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Consequently, platelet count has been implicated as
a prognostic marker for various severity scoring systems, such as Multiple Organ
Dysfunction Score (MODS)<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>]</sup>, Sequential Organ Failure
Assessment (SOFA)<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>,
Logistic Organ Dysfunction Score (LODS)<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>, and others<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>There are basically four mechanisms that can decrease platelet counts: decreased
production, increased destruction (immune-or nonimmune-mediated), hemodilution and
sequestration (as in hypersplenism)<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r9" ref-type="bibr">9</xref>]</sup>. In
the general intensive care unit (ICU) scenario, thrombocytopenia may occur in up to
20% admissions, 35% of surgical hospitalizations and 45% of trauma
admissions<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Considering cardiac surgery patients, thrombocytopenia is
an extremely frequent finding, varying from 35% to 65% of all
cases<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>,
and patients after percutaneous coronary interventions (PCI) are also prone to
develop major thrombocytopenia, <italic>i.e</italic>. &#x0003c;100.000/&#x000b5;L, in
2.4-9.2% of cases<sup>[<xref rid="r11" ref-type="bibr">11</xref>-<xref rid="r13" ref-type="bibr">13</xref>]</sup>.</p><p>Causes for thrombocytopenia following cardiac surgery are believed to be
multifactorial, with cardiopulmonary bypass (CPB) installation as the main culprit.
However, with the development of off-pump coronary artery bypass grafting (CABG) and
more recent transcatheter valve procedures, such as transcatheter aortic valve
replacement (TAVR), new questions arose regarding thrombocytopenia in a post-cardiac
surgery setting. Even without the use of CPB, platelet count continues to drop,
which rendered further doubts not only as to the origin of this problem, but also to
its clinical implications. To date, there are very few studies available which
tackle this issue, with some showing strong correlation between the occurrence of
severe thrombocytopenia after TAVR and higher mortality rates<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p><p>When we consider the valve-in-valve (ViV) scenario and the incidence of
thrombocytopenia, even less can be said. Although transcatheter ViV procedures is a
well-established option for treatment of degenerated bioprosthesis in high and
extreme-risk patients<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>, and the incidence of thrombocytopenia is high after
these procedures, there are no available data in the literature addressing this
problem. Therefore, little is known about this phenomenon and its correlation with
unfavorable events.</p></sec><sec sec-type="methods"><title>METHODS</title><p>We carried on a retrospective, single-centre, database analysis study of all
consecutive patients who underwent transcatheter ViV implantation from May 2015
until March 2017. A total of 30 patients underwent transcatheter ViV procedures at
our institution during this period, with the majority of them performed through
transapical access (82%). One patient who had transcatheter mitral ViV and
concomitant TAVR, and one patient who received two concomitant ViVs for mitral and
tricuspid valve degeneration, were not included in this study, leaving the remainder
of 28 patients. Of these, 5 were performed on degenerated bioprosthetic valves on
aortic position, 18 on mitral and 5 on tricuspid. Four of the five patients in the
tricuspid group had transjugular access, and one patient was accessed through a
transatrial right anterior thoracotomy. All patients who underwent ViV procedures
were deemed high or extreme risk for conventional approach, and were thoroughly
discussed by our heart team. Surgical procedures were conducted in a hybrid
operating room, using fluoroscopic and echocardiographic guidance. The transcatheter
valve utilized in all patients was the Braile Inovare<sup>&#x000ae;</sup> prosthesis,
a balloon expandable valve platform with a chromium-cobalt stent frame, widely used
in Brazilian experience<sup>[<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>]</sup>.</p><p>Pre- and postoperative data were collected and the platelet curves were elaborated,
starting with the first value upon ICU admission, and taking into account daily
values of platelet counts until the 10<sup>th</sup> postoperative day. Postoperative
bleeding was also quantified and correlated with the drop in platelet values, as
well as the occurrence of other adverse events, such as paravalvular regurgitation,
acute renal failure and death. All definitions were in accordance with the Valve
Academic Research Consortium (VARC-2) standardized endpoint definitions for TAVR
consensus document<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>.</p><p>Furthermore, data was collected from all conventional reoperations for degenerated
bioprosthetic valve replacement, performed at our institution during the same period
to serve as a control group. A total of 146 patients were analyzed and 74 were
included, after patients with active infective endocarditis, combined procedures
(<italic>i.e</italic>.: CABG + valve replacement), previous valve repair and
non-replacement, use of mechanical valves at any point, septic shock, previous
hematologic disease, pregnant women and those with perioperative mortality were
excluded. Postoperative platelet curves between both groups were compared and
correlated with clinical outcomes.</p><sec><title>Statistical Analysis</title><p>For the variables with homogeneous distribution, parametric tests were performed
and the results were presented in mean and standard deviation. As for the
variables with non-homogeneous distribution, we performed non-parametric tests
and the results are presented in median and interquartile range. Chi-square test
and Fisher's exact test were used to compare the categorical variables. Analysis
of the quantitative variables was performed by comparing means using the t-test
or Kruskal-Wallis test. We considered as statistically significant differences
the results with values of <italic>P</italic>&#x0003c;0.05. Statistical analysis were
conducted using IBM SPSS Statistics<sup>&#x000ae;</sup> 20 for Windows (Chicago,
IL, United States).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Thrombocytopenia occurred in 100% of patients who underwent transcatheter ViV
implantation, regardless of the position where the degenerated bioprosthesis was
originally placed. Seven (25%) patients experienced mild thrombocytopenia, with the
nadir of platelet counts between 100.000-150.000/&#x000b5;L, 15 (54%) showed moderate
thrombocytopenia (50.000-100.000/&#x000b5;L) and 6 (21%) presented with severe
thrombocytopenia postoperatively (&#x0003c;50.000/&#x000b5;L), as shown in <xref rid="t1" ref-type="table">Table 1</xref>. Within this group, there was no
statistical difference between the degree of thrombocytopenia presented and the
occurrence of adverse events, such as death, major bleeding, acute renal failure and
sepsis. Regarding baseline characteristics, there was also no significant factor
that could predict a higher risk of postoperative thrombocytopenia.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline and postoperative characteristics of valve-in-valve patients
according to the degree of thrombocytopenia, in absolute values.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">General</th><th align="center" rowspan="1" colspan="1">Mild thrombocytopenia
(&#x02265;100.000/&#x000b5;L)<break/>7 patients</th><th align="center" rowspan="1" colspan="1">Moderate thrombocytopenia
(&#x0003c;100.000/&#x000b5;L)<break/>15 patients</th><th align="center" rowspan="1" colspan="1">Severe thrombocytopenia
(&#x02264;50.000/&#x000b5;L)<break/>6 patients</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Preoperative</bold>
</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Age</td><td align="center" rowspan="1" colspan="1">60 (16-82)</td><td align="center" rowspan="1" colspan="1">59 (16-80)</td><td align="center" rowspan="1" colspan="1">60 (34-81)</td><td align="center" rowspan="1" colspan="1">62 (21-78)</td><td align="center" rowspan="1" colspan="1">0.796</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;EuroSCORE II</td><td align="center" rowspan="1" colspan="1">7.45 (2,86-32.87)</td><td align="center" rowspan="1" colspan="1">9.85 (1.52-32.93)</td><td align="center" rowspan="1" colspan="1">8.75 (2.52-26.87)</td><td align="center" rowspan="1" colspan="1">10,10 (1.52-26.46)</td><td align="center" rowspan="1" colspan="1">0.943</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;NYHA I-II</td><td align="center" rowspan="1" colspan="1">9 (32.14)</td><td align="center" rowspan="1" colspan="1">3 (42.85)</td><td align="center" rowspan="1" colspan="1">4 (26.6)</td><td align="center" rowspan="1" colspan="1">2 (40)</td><td align="center" rowspan="1" colspan="1">0.753</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;NYHA III-IV</td><td align="center" rowspan="1" colspan="1">19 (67.85)</td><td align="center" rowspan="1" colspan="1">4 (57.14)</td><td align="center" rowspan="1" colspan="1">11 (73.3)</td><td align="center" rowspan="1" colspan="1">3 (60)</td><td align="center" rowspan="1" colspan="1">0.753</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Chronic renal
failure</td><td align="center" rowspan="1" colspan="1">15 (53.57)</td><td align="center" rowspan="1" colspan="1">4 (57.14)</td><td align="center" rowspan="1" colspan="1">8 (53.3)</td><td align="center" rowspan="1" colspan="1">3 (50)</td><td align="center" rowspan="1" colspan="1">0.967</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Atrial
fibrillation/flutter</td><td align="center" rowspan="1" colspan="1">17 (60.71)</td><td align="center" rowspan="1" colspan="1">5 (71.4)</td><td align="center" rowspan="1" colspan="1">10 (66.6)</td><td align="center" rowspan="1" colspan="1">2 (33.3)</td><td align="center" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;CAD</td><td align="center" rowspan="1" colspan="1">10 (35.71)</td><td align="center" rowspan="1" colspan="1">3 (42.8)</td><td align="center" rowspan="1" colspan="1">4 (26.6)</td><td align="center" rowspan="1" colspan="1">3 (50)</td><td align="center" rowspan="1" colspan="1">0.543</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;DM</td><td align="center" rowspan="1" colspan="1">7 (25)</td><td align="center" rowspan="1" colspan="1">2 (28.6)</td><td align="center" rowspan="1" colspan="1">4 (26.6)</td><td align="center" rowspan="1" colspan="1">1 (16.6)</td><td align="center" rowspan="1" colspan="1">0.856</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;CABG</td><td align="center" rowspan="1" colspan="1">7 (25)</td><td align="center" rowspan="1" colspan="1">2 (28.6)</td><td align="center" rowspan="1" colspan="1">4 (26.6)</td><td align="center" rowspan="1" colspan="1">1 (16.6)</td><td align="center" rowspan="1" colspan="1">0.856</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Previous prosthesis
stenosis</td><td align="center" rowspan="1" colspan="1">12 (43)</td><td align="center" rowspan="1" colspan="1">2 (29)</td><td align="center" rowspan="1" colspan="1">4 (40)</td><td align="center" rowspan="1" colspan="1">4 (67)</td><td align="center" rowspan="1" colspan="1">0.361</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Previous prosthesis
insufficiency</td><td align="center" rowspan="1" colspan="1">16 (57)</td><td align="center" rowspan="1" colspan="1">5 (71)</td><td align="center" rowspan="1" colspan="1">9 (60)</td><td align="center" rowspan="1" colspan="1">2 (33)</td><td align="center" rowspan="1" colspan="1">0.361</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No preoperative
thrombocytopenia</td><td align="center" rowspan="1" colspan="1">16 (57.14)</td><td align="center" rowspan="1" colspan="1">5 (71.4)</td><td align="center" rowspan="1" colspan="1">8 (53.3)</td><td align="center" rowspan="1" colspan="1">3 (50)</td><td align="center" rowspan="1" colspan="1">0.663</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mild preoperative
thrombocytopenia</td><td align="center" rowspan="1" colspan="1">8 (28.6)</td><td align="center" rowspan="1" colspan="1">2 (28.6)</td><td align="center" rowspan="1" colspan="1">5 (33.3)</td><td align="center" rowspan="1" colspan="1">1 (16.6)</td><td align="center" rowspan="1" colspan="1">0.732</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Moderate preoperative
thrombocytopenia</td><td align="center" rowspan="1" colspan="1">4 (14.28)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">2 (13.3)</td><td align="center" rowspan="1" colspan="1">2 (33.3)</td><td align="center" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Postoperative</bold>
</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absent or mild
paravalvular regurgitation</td><td align="center" rowspan="1" colspan="1">25 (92)</td><td align="center" rowspan="1" colspan="1">6 (85.7)</td><td align="center" rowspan="1" colspan="1">15 (100)</td><td align="center" rowspan="1" colspan="1">4 (80)</td><td align="center" rowspan="1" colspan="1">0.071</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Moderate paravalvular
regurgitation</td><td align="center" rowspan="1" colspan="1">2 (7.4)</td><td align="center" rowspan="1" colspan="1">1 (14.2)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">1 (20)</td><td align="center" rowspan="1" colspan="1">0.071</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Death</td><td align="center" rowspan="1" colspan="1">5 (17.8)</td><td align="center" rowspan="1" colspan="1">1 (14.28)</td><td align="center" rowspan="1" colspan="1">2 (13.33)</td><td align="center" rowspan="1" colspan="1">2 (33.3)</td><td align="center" rowspan="1" colspan="1">0.572</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Major bleeding</td><td align="center" rowspan="1" colspan="1">2 (7.1)</td><td align="center" rowspan="1" colspan="1">1 (14.3)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">1 (16.7)</td><td align="center" rowspan="1" colspan="1">0.196</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Acute renal
failure</td><td align="center" rowspan="1" colspan="1">17 (60.7)</td><td align="center" rowspan="1" colspan="1">3 (42.8)</td><td align="center" rowspan="1" colspan="1">10 (66.6)</td><td align="center" rowspan="1" colspan="1">4 (66.6)</td><td align="center" rowspan="1" colspan="1">0.542</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Sepsis</td><td align="center" rowspan="1" colspan="1">11 (39.28)</td><td align="center" rowspan="1" colspan="1">2 (28.6)</td><td align="center" rowspan="1" colspan="1">7 (46.6)</td><td align="center" rowspan="1" colspan="1">2(33.3)</td><td align="center" rowspan="1" colspan="1">0.677</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>CABG=coronary artery bypass grafting; CAD=coronary artery disease;
DM=diabetes mellitus; NYHA=New York Heart Association</p></fn></table-wrap-foot></table-wrap><sec><title>Platelet Curves for ViV Patients</title><p>In every position where the transcatheter valve was implanted, patients presented
with a drop in platelet counts already at the immediate postoperative period, as
shown in <xref ref-type="fig" rid="f1">Figure 1</xref>.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Mean platelet curves for all patients who underwent a valve-in-valve
procedure.</p><p>IPO=immediate postoperative period; PO=postoperative day;
ViV=valve-in-valve</p></caption><graphic xlink:href="rbccv-33-04-0362-g01"/></fig>
</p><p>Of note, four out of five patients who had a ViV implanted in tricuspid position
were preoperatively thrombocytopenic (average preoperative platelet count of
121.600/&#x000b5;L), two with mild and two with moderate thrombocytopenia. The
nadir of the tricuspid curve occurred at the 3<sup>rd</sup> postoperative day,
and by the 10<sup>th</sup> day, the mean platelet count had reached preoperative
values, but remained below the normal threshold of 150.000/&#x000b5;L. In this
subgroup of patients, the nadir of the platelet curve represented a 36.8% drop
from baseline.</p><p>In the mitral ViV subgroup, the preoperative platelet count was normal, with an
average of 180.278/&#x000b5;L. Thrombocytopenia was observed in the immediate
postoperative period, with the nadir occurring at the 2<sup>nd</sup>
postoperative day. Platelet counts began to rise from the 3<sup>rd</sup> day
onward, reaching normal values at the 7<sup>th</sup> postoperative day. In turn,
the nadir of the curve represented a 45.3% fall in relation to preoperative
values.</p><p>Aortic ViV patients also presented with normal preoperative platelet counts, and
had the highest values amongst the three subgroups: 198.400/&#x000b5;L. These
patients also experienced a platelet drop in the immediate postoperative period;
however, thrombocytopenic values were only reached at the 1<sup>st</sup>
postoperative day and persisted for longer. The nadir of the curve occurred in
the 4<sup>th</sup> day and, until the 10<sup>th</sup> day, regular preoperative
levels had not yet been reached, unlike the other two subgroups. The aortic ViV
subgroup of patients presented with the most expressive drop in platelet count:
62.3%.</p><p>Despite differences in absolute and percentage values between the three
subgroups, they were not statistically significant.</p></sec><sec><title>Platelet Curves for ViV <italic>vs.</italic> Conventional
Reoperations</title><p>The control group consisted of 74 patients who underwent conventional
reoperations to replace degenerated bioprosthesis at our institution, during the
same period. Of these, 31 were submitted to redo aortic valve replacement and 43
to redo mitral valve replacement. No isolated tricuspid redo patients could be
included because these were all congenital heart disease patients, who usually
underwent combined procedures, or had other complex cardiac repairs previously
done, which frequently utilized synthetic material and had to be excluded.</p><p>The comparison between patient's preoperative characteristics in each group is
shown in <xref rid="t2" ref-type="table">Tables 2</xref> and <xref rid="t3" ref-type="table">3</xref>. As expected, ViV patients were older and
had more comorbidities, such as chronic renal failure, coronary artery disease
and previous CABG. These differences were statistically significant and became
more evident in the mitral group comparison. Although EuroSCORE II was higher in
both ViV subgroups, this aspect showed no statistical difference.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Preoperative characteristics comparison between 18 mitral ViV patients
and 43 conventional mitral reoperations.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Mitral ViV</th><th align="center" rowspan="1" colspan="1">Mitral conventional reoperation</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">63.9</td><td align="center" rowspan="1" colspan="1">54.7</td><td align="center" rowspan="1" colspan="1">0.025</td></tr><tr><td align="left" rowspan="1" colspan="1">EuroSCORE II</td><td align="center" rowspan="1" colspan="1">11.48%</td><td align="center" rowspan="1" colspan="1">7.59%</td><td align="center" rowspan="1" colspan="1">0.075</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA I-II</td><td align="center" rowspan="1" colspan="1">4 (22.2)</td><td align="center" rowspan="1" colspan="1">10 (23.2)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA III-IV</td><td align="center" rowspan="1" colspan="1">14 (77.8)</td><td align="center" rowspan="1" colspan="1">33 (76.7)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic renal failure</td><td align="center" rowspan="1" colspan="1">12 (66.7)</td><td align="center" rowspan="1" colspan="1">13 (30.23)</td><td align="center" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation/flutter</td><td align="center" rowspan="1" colspan="1">12 (66.7)</td><td align="center" rowspan="1" colspan="1">26 (60.5)</td><td align="center" rowspan="1" colspan="1">0.775</td></tr><tr><td align="left" rowspan="1" colspan="1">CAD</td><td align="center" rowspan="1" colspan="1">6 (33.3)</td><td align="center" rowspan="1" colspan="1">4 (9.3)</td><td align="center" rowspan="1" colspan="1">0.051</td></tr><tr><td align="left" rowspan="1" colspan="1">DM</td><td align="center" rowspan="1" colspan="1">5 (27.8)</td><td align="center" rowspan="1" colspan="1">4 (9.3)</td><td align="center" rowspan="1" colspan="1">0.108</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous CABG</td><td align="center" rowspan="1" colspan="1">4 (22.2)</td><td align="center" rowspan="1" colspan="1">1 (2.3)</td><td align="center" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous prosthesis stenosis</td><td align="center" rowspan="1" colspan="1">6 (33.3)</td><td align="center" rowspan="1" colspan="1">29 (67.4)</td><td align="center" rowspan="1" colspan="1">0.022</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous prosthesis insufficiency</td><td align="center" rowspan="1" colspan="1">12 (66.7)</td><td align="center" rowspan="1" colspan="1">31 (72.1)</td><td align="center" rowspan="1" colspan="1">0.547</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>CABG=coronary artery bypass grafting; CAD=coronary artery disease;
DM=diabetes mellitus; NYHA=New York Heart Association</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Preoperative characteristics comparison between 5 aortic ViV patients and
31 conventional aortic reoperations.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Aortic ViV</th><th align="center" rowspan="1" colspan="1">Aortic conventional reoperation</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">79</td><td align="center" rowspan="1" colspan="1">61.8</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">EuroSCORE II</td><td align="center" rowspan="1" colspan="1">8.78%</td><td align="center" rowspan="1" colspan="1">7.28%</td><td align="center" rowspan="1" colspan="1">0.161</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA I-II</td><td align="center" rowspan="1" colspan="1">2 (40)</td><td align="center" rowspan="1" colspan="1">13 (41.9)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA III-IV</td><td align="center" rowspan="1" colspan="1">3 (60)</td><td align="center" rowspan="1" colspan="1">17 (54.8)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic renal failure</td><td align="center" rowspan="1" colspan="1">3 (60)</td><td align="center" rowspan="1" colspan="1">9 (29)</td><td align="center" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation/flutter</td><td align="center" rowspan="1" colspan="1">2 (40)</td><td align="center" rowspan="1" colspan="1">10 (32.3)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">CAD</td><td align="center" rowspan="1" colspan="1">4 (90)</td><td align="center" rowspan="1" colspan="1">9 (29)</td><td align="center" rowspan="1" colspan="1">0.047</td></tr><tr><td align="left" rowspan="1" colspan="1">DM</td><td align="center" rowspan="1" colspan="1">2 (40)</td><td align="center" rowspan="1" colspan="1">5 (16.1)</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous CABG</td><td align="center" rowspan="1" colspan="1">3 (60)</td><td align="center" rowspan="1" colspan="1">4 (12.9)</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous prosthesis stenosis</td><td align="center" rowspan="1" colspan="1">4 (90)</td><td align="center" rowspan="1" colspan="1">23 (74.2)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous prosthesis insufficiency</td><td align="center" rowspan="1" colspan="1">1 (20)</td><td align="center" rowspan="1" colspan="1">23 (74.2)</td><td align="center" rowspan="1" colspan="1">0.034</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>CABG=coronary artery bypass grafting; CAD=coronary artery disease;
DM=diabetes mellitus; NYHA=New York Heart Association</p></fn></table-wrap-foot></table-wrap><p>The comparison between conventional mitral valve reoperation and mitral ViV
showed very similar platelet curves, as shown in <xref ref-type="fig" rid="f2">Figure 2</xref>. Thrombocytopenia was present at the immediate
postoperative period as well, the nadir occurred at day 3 and platelet levels
returned to baseline by day 7. The drop in platelet count represented 47.73%
from baseline, and the difference between both groups was not statistically
significant until the 7<sup>th</sup> postoperative day. However, by the
10<sup>th</sup> day, conventional redo patients had a higher platelet counts
than ViV, with statistical significance. Only one (2%) patient in the
conventional surgery group did not experience postoperative
thrombocytopenia.</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Comparison between mean platelet values for conventional mitral
reoperation and mitral valve-in-valve (VIV) patients.</p></caption><graphic xlink:href="rbccv-33-04-0362-g02"/></fig>
</p><p>Differences between conventional and transcatheter groups were more pronounced in
aortic patients. Conventional surgery patients presented thrombocytopenia in the
immediate postoperative period and the nadir was sooner, on the 3<sup>rd</sup>
postoperative day. The curves crossed and recovery of platelet count was faster
in the conventional group, reaching normal preoperative levels by the
6<sup>th</sup> day and presenting a considerable difference by the
10<sup>th</sup> postoperative day.</p><p>The nadir of the curve was on the 4<sup>th</sup> day and represented a drop of
52.4% in platelet count.</p><p>From the end of the fist week until the 10<sup>th</sup> day, the highest level of
thrombocytopenia in the ViV group was statistically significant, as shown in
<xref ref-type="fig" rid="f3">Figure 3</xref>. In the aortic control group,
only 3 (7.5%) patients remained with normal platelet counts in the postoperative
period.</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Comparison between mean platelet values for conventional aortic
reoperation and aortic valve-in-valve (VIV) patients.</p></caption><graphic xlink:href="rbccv-33-04-0362-g03"/></fig>
</p></sec><sec><title>Predictors and Outcomes</title><p>To further refine the data analysis, we divided all ViV patients considering the
degree of thrombocytopenia presented, according to each individual's initial
platelet count (drop &#x02265;50% or &#x0003c;50%), instead of accounting only for the
absolute lowest platelet value. This is shown in <xref rid="t4" ref-type="table">Table 4</xref>, where 16 (57%) patients presented with a drop in platelets
&#x02265;50% and 12 (43%) had less than a 50% drop.</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Baseline and postoperative characteristics of valve-in-valve patients
according to the degree of thrombocytopenia in relation to each
individual's baseline platelet value and proportional drop in platelet
count.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Drop &#x0003c;50% (n=12)</th><th align="center" rowspan="1" colspan="1">Drop &#x0003e;50% (n=16)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Preoperative</bold>
</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Age</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">0.205</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;EuroSCORE II</td><td align="center" rowspan="1" colspan="1">10 (2-33)</td><td align="center" rowspan="1" colspan="1">9 (3-26)</td><td align="center" rowspan="1" colspan="1">0.478</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;NYHA I-II</td><td align="center" rowspan="1" colspan="1">4 (33.3)</td><td align="center" rowspan="1" colspan="1">5 (31.25)</td><td align="center" rowspan="1" colspan="1">0.612</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;NYHA III-IV</td><td align="center" rowspan="1" colspan="1">8 (66.6)</td><td align="center" rowspan="1" colspan="1">11 (68.75)</td><td align="center" rowspan="1" colspan="1">0.612</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Chronic renal
failure</td><td align="center" rowspan="1" colspan="1">6 (50)</td><td align="center" rowspan="1" colspan="1">9 (56.25)</td><td align="center" rowspan="1" colspan="1">0.521</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Atrial
fibrillation/flutter</td><td align="center" rowspan="1" colspan="1">8 (66.6)</td><td align="center" rowspan="1" colspan="1">9 (56.25)</td><td align="center" rowspan="1" colspan="1">0.435</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;CAD</td><td align="center" rowspan="1" colspan="1">3 (25)</td><td align="center" rowspan="1" colspan="1">7 (43.75)</td><td align="center" rowspan="1" colspan="1">0.268</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;DM</td><td align="center" rowspan="1" colspan="1">1 (8.3)</td><td align="center" rowspan="1" colspan="1">6 (37,5)</td><td align="center" rowspan="1" colspan="1">0.091</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;CABG</td><td align="center" rowspan="1" colspan="1">3 (25)</td><td align="center" rowspan="1" colspan="1">4 (25)</td><td align="center" rowspan="1" colspan="1">0.666</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Previous prosthesis
stenosis</td><td align="center" rowspan="1" colspan="1">6 (50)</td><td align="center" rowspan="1" colspan="1">6 (37.5)</td><td align="center" rowspan="1" colspan="1">0.391</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Previous prosthesis
insufficiency</td><td align="center" rowspan="1" colspan="1">6 (50)</td><td align="center" rowspan="1" colspan="1">10 (62.5)</td><td align="center" rowspan="1" colspan="1">0.391</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absent or mild
paravalvular leak</td><td align="center" rowspan="1" colspan="1">11 (91.6)</td><td align="center" rowspan="1" colspan="1">15 (93.75)</td><td align="center" rowspan="1" colspan="1">0.389</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Moderate
paravalvular leak</td><td align="center" rowspan="1" colspan="1">1 (8.3)</td><td align="center" rowspan="1" colspan="1">1 (6.25)</td><td align="center" rowspan="1" colspan="1">0.389</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No preoperative
thrombocytopenia</td><td align="center" rowspan="1" colspan="1">3 (25)</td><td align="center" rowspan="1" colspan="1">13 (81.25)</td><td align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mild preoperative
thrombocytopenia</td><td align="center" rowspan="1" colspan="1">6 (50)</td><td align="center" rowspan="1" colspan="1">2 (12.5)</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Moderate
preoperative thrombocytopenia</td><td align="center" rowspan="1" colspan="1">3 (25)</td><td align="center" rowspan="1" colspan="1">&#x000a0;1 (6.25)</td><td align="center" rowspan="1" colspan="1">0.196</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Postoperative</bold>
</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absent or mild
paravalvular regurgitation</td><td align="center" rowspan="1" colspan="1">11 (91.6)</td><td align="center" rowspan="1" colspan="1">15 (93.75)</td><td align="center" rowspan="1" colspan="1">0.389</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Moderate
paravalvular regurgitation</td><td align="center" rowspan="1" colspan="1">1 (8.3)</td><td align="center" rowspan="1" colspan="1">1 (6.25)</td><td align="center" rowspan="1" colspan="1">0.389</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Death</td><td align="center" rowspan="1" colspan="1">2 (16.6)</td><td align="center" rowspan="1" colspan="1">3 (18.75)</td><td align="center" rowspan="1" colspan="1">0.643</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Major bleeding</td><td align="center" rowspan="1" colspan="1">1 (8.3)</td><td align="center" rowspan="1" colspan="1">1 (6.250)</td><td align="center" rowspan="1" colspan="1">0.683</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Acute renal
failure</td><td align="center" rowspan="1" colspan="1">7 (58.3)</td><td align="center" rowspan="1" colspan="1">10 (62.5)</td><td align="center" rowspan="1" colspan="1">0.565</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Sepsis</td><td align="center" rowspan="1" colspan="1">5 (41.6)</td><td align="center" rowspan="1" colspan="1">6 (37.5)</td><td align="center" rowspan="1" colspan="1">0.565</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>CABG=coronary artery bypass grafting; CAD=coronary artery disease;
DM=diabetes mellitus; NYHA=New York Heart Association</p></fn></table-wrap-foot></table-wrap><p>There were also no statistically significant differences between patient's
characteristics in both groups, except for the preoperative platelet count. A
normal platelet count from baseline was significantly correlated with a greater
fall in platelet levels, over 50%. Paradoxically, patients who already had mild
to moderate preoperative thrombocytopenia experienced a less pronounced drop in
platelet count. Nevertheless, a drop over 50% was not correlated with higher
risk of mortality, major bleeding, acute renal failure, or other studied
outcomes.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In this retrospective study, we aimed to correlate pre- and postoperative
characteristics of ViV patients with postoperative thrombocytopenia, which occurred
in all of our patients. There were expected preoperative differences between
patients in the ViV group and in the conventional reoperation group. Naturally,
those who underwent ViV procedures had been deemed as high/extremely high risk for
conventional surgery by our heart team, and therefore were older, with more
comorbidities, a higher incidence of chronic renal failure and previous CABG.
Nevertheless, the EuroSCORE II values, although higher for the ViV group, did not
show a statistically significant difference between both groups.</p><p>Surprisingly, although thrombocytopenia is regarded as multifactorial, it has, for a
long time, been attributed mainly to the installation of CPB, since upon initiation
of bypass platelets drop to approximately 50% from baseline<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. The unavoidable
hemodilution that succeeds, the sheer stress to the platelets, by roller or
centrifugal pumps, and extracorporeal plastic tubing interaction, have been commonly
charged with causing their ultimate destruction<sup>[<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r19" ref-type="bibr">19</xref>]</sup>.
Other well-established factors associated with thrombocytopenia in cardiac surgery
are the use of intra-aortic balloon pumps (IABP), sepsis and drug-related, mainly
heparin-induced thrombocytopenia (HIT), a rare phenomenon with incidence around
1%<sup>[<xref rid="r11" ref-type="bibr">11</xref>-<xref rid="r13" ref-type="bibr">13</xref>]</sup>.</p><p>However, thrombocytopenia occurred in a similar fashion in patients submitted to
transcatheter ViV implants, which were not placed in CPB. Platelet curves for
conventional surgery and mitral ViV implants were particularly similar, with no
statistical difference until the 7<sup>th</sup> postoperative day, whereas curves
comparing procedures for the aortic position showed significant difference, with a
more pronounced and prolonged platelet drop in ViV implants.</p><p>Therefore, we may infer that, although multifactorial, CPB may not necessarily be the
main cause of thrombocytopenia after valvular heart surgery, and platelet
interaction with the bioprosthetic valve components such as bovine pericardium,
Teflon felts, chromium-cobalt or nitinol stent frames, may play a much more
important role. This could explain why aortic ViV patients experienced a higher
degree of thrombocytopenia in comparison to mitral ViV.</p><p>Physiologically, transvalvular pressure and velocity gradients are higher in aortic
than in mitral position, which could justify higher stress levels to platelets and
translate into greater platelet degradation and consumption.</p><p>To the authors' knowledge, this is the first study to try to correlate the degree of
thrombocytopenia after ViV procedures and the incidence of adverse events. Jilaihawi
et al.<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup> conducted
a similar study regarding thrombocytopenia, comparing 246 TAVR patients (200
transfemoral and 46 transapical) with 57 high-risk surgical aortic valve replacement
(SAVR) patients. They found very similar platelet curves between both groups, with a
greater decrease in the SAVR group, unlike our ViV aortic group comparison. Major
thrombocytopenia occurred in over one third of patients in the TAVR group, which
proved to be benign and self-limited in most cases. As in our study, they were
unable to find a significant relationship between moderate/severe thrombocytopenia
and adverse events, when platelet count normalizes before the end of the first
postoperative month. However, in the rare cases in which thrombocytopenia was found
to be persistent (lasting longer than 30&#x000b1;10 days), this was an independent
predictor of mortality (HR 3,27).</p><p>In a comparable fashion, Dvir et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup> conducted a study with 488 TAVR patients seeking an
association between acquired thrombocytopenia and clinical outcomes. Postoperative
thrombocytopenia was extremely common and transient, with 90.2% of patients
presenting with no or mild thrombocytopenia at discharge, but 36.1% showed
significant thrombocytopenia.</p><p>Interestingly, they found a nadir of platelet count &#x0003c;50.000/&#x000b5;L to be a
highly specific marker for 30-day mortality. The occurrence of severe
thrombocytopenia, analyzed through multivariate logistic regression, proved to be
and independent risk factor for one-year mortality (OR 3,44).</p><p>The authors were able to correlate the degree of thrombocytopenia with the following
adverse events at 30 days: cardiovascular death, sepsis, major bleeding, greater
units of blood transfusion, acute kidney injury (AKI) and prolonged ICU stay.
Therefore, they propose that thrombocytopenia can be used as an excellent prognostic
marker for adverse short- and long-term outcomes after TAVR.</p><p>In our study population, there was no significant correlation between the degree of
thrombocytopenia and the incidence of adverse events, and no preoperative or
immediate postoperative factors could predict the occurrence of thrombocytopenia.
Jilaihawi et al.<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>
found significant association between moderate/severe persistent thrombocytopenia
and hepatic cirrhosis, male sex and preoperative thrombocytopenia. Dvir et
al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>, on
the other hand, found the following characteristics associated with severe
thrombocytopenia after TAVR: preoperative thrombocytopenia, leukopenia, vascular
access complications, major bleeding, multiple transfusions, AKI, and sepsis. In
contrast, our ViV group analysis showed that patients with normal preoperative
platelet counts were at a higher risk of presenting with a greater drop in platelet
counts &#x0003e;50% than patients who already presented with mild or even moderate
thrombocytopenia.</p><p>Two other studies focused on thrombocytopenia after TAVR were conducted by Flaherty
et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>, who
analyzed 90 TAVR patients who received the Edwards SAPIEN valve; and McCabe et
al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>,
which compared 112 TAVR patients with 105 balloon aortic valvuloplasties (BAV)
patients. Flaherty et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup> identified that thrombocytopenia occurred in 79% of
post-TAVR patients, and independent preoperative predictors for moderate/severe
thrombocytopenia were baseline thrombocytopenia, leaner body mass, smaller aortic
valve area, higher peak aortic jet velocity and worse renal function. The occurrence
of major thrombocytopenia was a predictor for major vascular complications and major
bleeding. The study conducted by McCabe et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>, on the other hand, found that, although
there was a significant difference in the prevalence of thrombocytopenia in TAVR
patients (69%) in comparison to BAV (37%), this did not translate into any major
clinical outcomes, except for an increased use of hemocomponents. The possibility of
severe or persistent thrombocytopenia following TAVR remains a major concern, since
bleeding following TAVR is independently associated with increased mortality.</p><p>Furthermore, there may be more on the issue of thrombocytopenia than meets the eye. A
Polish study, conducted by Mitrosz et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>, analyzed 32 TAVR patients and found that
the only factor which positively correlated with drop platelets was the amount of
iodinated contrast used during the procedure. This aspect was not taken into
consideration in any of the other studies mentioned above.</p><p>Interestingly, in all TAVR studies, there was a considerable number of patients who
did not present thrombocytopenia after the procedure. However, in our ViV study, all
patients developed postoperative thrombocytopenia. These were all high-risk
patients, with similar baseline characteristics, whose differences can be credited
mainly to the surgical procedure itself (ViV rather than TAVR) and to the type of
valve prosthesis utilized (Braile INOVARE, Medtronic COREVALVE and Edwards SAPIEN).
Considering differences in surgical bioprosthetic valves as an example, Piccardo et
al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup> have
already shown a higher incidence of thrombocytopenia after surgical implant of the
Freedom Solo valve in comparison to Carpentier-Edwards Perimount (25%
<italic>vs.</italic> 3%, respectively), which did not translate into deleterious
events.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Thrombocytopenia after ViV procedures remains an extremely frequent finding, with
unknown origins. In our study population, this phenomenon occurred in all patients;
however, the degree of thrombocytopenia could not be associated with the incidence
of adverse outcomes, probably due to a limited number of patients. Thrombocytopenia,
therefore, did not prove itself to be a marker of worse prognosis in our ViV
population.</p><p>Since previous studies, with larger series of patients, have shown positive
implications of the decrease in platelet counts and higher postoperative risk in
TAVR patients, we believe that further investigation of this matter in the ViV
cohort should be encouraged.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">RCS</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intel-lectual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LP</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intellec-tual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GV</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intellec-tual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">JA</td><td align="left" valign="top" rowspan="1" colspan="1">Agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved; final ap-proval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LLA</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HR</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ROS</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FT</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PMAP</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">JHP</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FBJ</td><td align="left" valign="top" rowspan="1" colspan="1">Final approval of the version to be
published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Cardiovascular Surgery Division, Instituto do
Cora&#x000e7;&#x000e3;o do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina
da Universidade de S&#x000e3;o Paulo (InCor-HCFMUSP), S&#x000e3;o Paulo, SP,
Brazil.</p></fn><fn fn-type="COI-statement"><p>Conflict of Interest: The authors would like to declare that the institution has
received research grants from Braile Biom&#x000e9;dica.</p></fn></fn-group><fn-group><fn fn-type="supported-by"><p>Financial Support: Partial external financial support was received for the
development of this study, in the form of donations of transcatheter heart
valves performed by Braile Biom&#x000e9;dica.</p></fn><fn fn-type="COI-statement"><p>Conflict of Interest: The authors would like to declare that the institution has
received research grants from Braile Biom&#x000e9;dica.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HL</given-names></name><name><surname>Aguilera</surname><given-names>C</given-names></name><name><surname>Knopf</surname><given-names>KB</given-names></name><name><surname>Chen</surname><given-names>TM</given-names></name><name><surname>Maslove</surname><given-names>DM</given-names></name><name><surname>Kuschner</surname><given-names>WG</given-names></name></person-group><article-title>Thrombocytopenia in the intensive care unit</article-title><source>J Intensive Care Med</source><year>2013</year><volume>28</volume><issue>5</issue><fpage>268</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">22232201</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanderschueren</surname><given-names>S</given-names></name><name><surname>De Weerdt</surname><given-names>A</given-names></name><name><surname>Malbrain</surname><given-names>M</given-names></name><name><surname>Vankersschaever</surname><given-names>D</given-names></name><name><surname>Frans</surname><given-names>E</given-names></name><name><surname>Wilmer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Thrombocytopenia and prognosis in intensive care</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><issue>6</issue><fpage>1871</fpage><lpage>1876</lpage><pub-id pub-id-type="pmid">10890635</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>JC</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Christou</surname><given-names>NV</given-names></name><name><surname>Bernard</surname><given-names>GR</given-names></name><name><surname>Sprung</surname><given-names>CL</given-names></name><name><surname>Sibbald</surname><given-names>WJ</given-names></name></person-group><article-title>Multiple organ dysfunction score: a reliable descriptor of a
complex clinical outcome</article-title><source>Crit Care Med</source><year>1995</year><volume>23</volume><issue>10</issue><fpage>1638</fpage><lpage>1652</lpage><pub-id pub-id-type="pmid">7587228</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strand</surname><given-names>K</given-names></name><name><surname>Flaatten</surname><given-names>H</given-names></name></person-group><article-title>Severity scoring in the ICU: a review</article-title><source>Acta Anaesthesiol Scand</source><year>2008</year><volume>52</volume><issue>4</issue><fpage>467</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">18339152</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>FL</given-names></name><name><surname>Bota</surname><given-names>DP</given-names></name><name><surname>Bross</surname><given-names>A</given-names></name><name><surname>M&#x000e9;lot</surname><given-names>C</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group><article-title>Serial evaluation of the SOFA score to predict outcome in
critically ill patients</article-title><source>JAMA</source><year>2001</year><volume>286</volume><issue>14</issue><fpage>1754</fpage><lpage>1758</lpage><pub-id pub-id-type="pmid">11594901</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Gall</surname><given-names>JR</given-names></name><name><surname>Klar</surname><given-names>J</given-names></name><name><surname>Lemeshow</surname><given-names>S</given-names></name><name><surname>Saulnier</surname><given-names>F</given-names></name><name><surname>Alberti</surname><given-names>C</given-names></name><name><surname>Artigas</surname><given-names>A</given-names></name><etal/></person-group><article-title>The Logistic Organ Dysfunction system. A new way to assess organ
dysfunction in the intensive care unit</article-title><person-group person-group-type="author"><collab>ICU Scoring Group</collab></person-group><source>JAMA</source><year>1996</year><volume>276</volume><issue>10</issue><fpage>802</fpage><lpage>810</lpage><pub-id pub-id-type="pmid">8769590</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapsang</surname><given-names>AG</given-names></name><name><surname>Shyam</surname><given-names>DC</given-names></name></person-group><article-title>Scoring systems in the intensive care unit: a
compendium</article-title><source>Indian J Crit Care Med</source><year>2014</year><volume>18</volume><issue>4</issue><fpage>220</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">24872651</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crowther</surname><given-names>MA</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Meade</surname><given-names>MO</given-names></name><name><surname>Griffith</surname><given-names>LE</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Arnold</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Thrombocytopenia in medical-surgical critically ill patients:
prevalence, incidence, and risk factors</article-title><source>J Crit Care</source><year>2005</year><volume>20</volume><issue>4</issue><fpage>348</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">16310606</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drews</surname><given-names>RE</given-names></name><name><surname>Weinberger</surname><given-names>SE</given-names></name></person-group><article-title>Thrombocytopenic disorders in critically ill
patients</article-title><source>Am J Respir Crit Care Med</source><year>2000</year><volume>162</volume><issue>2</issue><issue-part>Pt 1</issue-part><fpage>347</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">10934051</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezende</surname><given-names>E</given-names></name><name><surname>Morais</surname><given-names>G</given-names></name><name><surname>Silva Junior</surname><given-names>JM</given-names></name><name><surname>Oliveira</surname><given-names>AM</given-names></name><name><surname>Souza</surname><given-names>JM</given-names></name><name><surname>Toledo</surname><given-names>DO</given-names></name><etal/></person-group><article-title>Thrombocytopenia in cardiac surgery: diagnostic and prognostic
importance</article-title><source>Rev Bras Cir Cardiovasc</source><year>2011</year><volume>26</volume><issue>1</issue><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">21881711</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jilaihawi</surname><given-names>H</given-names></name><name><surname>Doctor</surname><given-names>N</given-names></name><name><surname>Chakravarty</surname><given-names>T</given-names></name><name><surname>Kashif</surname><given-names>M</given-names></name><name><surname>Mirocha</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><etal/></person-group><article-title>Major thrombocytopenia after balloon-expandable transcatheter
aortic valve replacement: prognostic implications and comparison to surgical
aortic valve replacement</article-title><source>Catheter Cardiovasc Interv</source><year>2015</year><volume>85</volume><issue>1</issue><fpage>130</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">24677617</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthai Jr</surname><given-names>WH</given-names></name></person-group><article-title>Thrombocytopenia in cardiovascular patients: diagnosis and
management</article-title><source>Chest</source><year>2005</year><volume>127</volume><issue>2</issue><supplement>Suppl</supplement><fpage>46S</fpage><lpage>52S</lpage><pub-id pub-id-type="pmid">15706030</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>J</given-names></name><name><surname>Kadosh</surname><given-names>B</given-names></name><name><surname>Gulkarov</surname><given-names>IM</given-names></name><name><surname>Salemi</surname><given-names>A</given-names></name></person-group><article-title>Heparin induced thrombocytopenia and cardiac surgery: a
comprehensive review</article-title><source>J Blood Disord Transfus</source><year>2011</year><issue>S2</issue><fpage>003</fpage><lpage>003</lpage></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dvir</surname><given-names>D</given-names></name><name><surname>G&#x000e9;n&#x000e9;reux</surname><given-names>P</given-names></name><name><surname>Barbash</surname><given-names>IM</given-names></name><name><surname>Kodali</surname><given-names>S</given-names></name><name><surname>Ben-Dor</surname><given-names>I</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><etal/></person-group><article-title>Acquired thrombocytopenia after transcatheter aortic valve
replacement: clinical correlates and association with
outcomes</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><issue>38</issue><fpage>2663</fpage><lpage>2671</lpage><pub-id pub-id-type="pmid">24598983</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>RA</given-names></name><name><surname>Otto</surname><given-names>CM</given-names></name><name><surname>Bonow</surname><given-names>RO</given-names></name><name><surname>Carabello</surname><given-names>BA</given-names></name><name><surname>Erwin</surname><given-names>JP 3rd</given-names></name><name><surname>Fleisher</surname><given-names>LA</given-names></name><etal/></person-group><article-title>2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the
management of patients with valvular heart disease. A Report of the American
College of Cardiology/American Heart Association Task Force on Clinical
Practice Guidelines</article-title><source>Circulation</source><year>2017</year><volume>135</volume><issue>25</issue><fpage>e1159</fpage><lpage>e1195</lpage><pub-id pub-id-type="pmid">28298458</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaia</surname><given-names>DF</given-names></name><name><surname>Couto</surname><given-names>A</given-names></name><name><surname>Breda</surname><given-names>JR</given-names></name><name><surname>Ferreira</surname><given-names>CB</given-names></name><name><surname>Macedo</surname><given-names>MT</given-names></name><name><surname>Gimenes</surname><given-names>MV</given-names></name><etal/></person-group><article-title>Transcatheter aortic valve-in-valve implantation: a selection
change?</article-title><source>Rev Bras Cir Cardiovasc</source><year>2012</year><volume>27</volume><issue>3</issue><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">23288175</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaia</surname><given-names>DF</given-names></name><name><surname>Breda</surname><given-names>JR</given-names></name><name><surname>Duarte Ferreira</surname><given-names>CB</given-names></name><name><surname>Marcondes de Souza</surname><given-names>JA</given-names></name><name><surname>Macedo</surname><given-names>MT</given-names></name><name><surname>Gimenes</surname><given-names>MV</given-names></name><etal/></person-group><article-title>New Braile Inovare transcatheter aortic prosthesis: clinical
results and follow-up</article-title><source>EuroIntervention</source><year>2015</year><volume>11</volume><issue>6</issue><fpage>682</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">26499221</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kappetein</surname><given-names>AP</given-names></name><name><surname>Head</surname><given-names>SJ</given-names></name><name><surname>G&#x000e9;n&#x000e9;reux</surname><given-names>P</given-names></name><name><surname>Piazza</surname><given-names>N</given-names></name><name><surname>van Mieghem</surname><given-names>NM</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Updated standardized endpoint definitions for transcatheter
aortic valve implantation: the Valve Academic Research Consortium-2
consensus document</article-title><source>J Thorac Cardiovasc Surg</source><year>2013</year><volume>145</volume><issue>1</issue><fpage>6</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">23084102</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>JF</given-names></name><name><surname>Daniel</surname><given-names>TD</given-names></name><name><surname>Towbridge</surname><given-names>EA</given-names></name></person-group><article-title>Acute and chronic changes in platelet volume and count after
cardiopulmonary bypass induced thrombocytopenia in man</article-title><source>Thromb Haemost</source><year>1987</year><volume>57</volume><issue>1</issue><fpage>55</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">3590081</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaherty</surname><given-names>MP</given-names></name><name><surname>Mohsen</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>JB 4th</given-names></name><name><surname>Bartoli</surname><given-names>CR</given-names></name><name><surname>Schneibel</surname><given-names>E</given-names></name><name><surname>Rawasia</surname><given-names>W</given-names></name><etal/></person-group><article-title>Predictors and clinical impact of pre-existing and acquired
thrombocytopenia following transcatheter aortic valve
replacement</article-title><source>Catheter Cardiovasc Interv</source><year>2015</year><volume>85</volume><issue>1</issue><fpage>118</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">25204308</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCabe</surname><given-names>JM</given-names></name><name><surname>Huang</surname><given-names>PH</given-names></name><name><surname>Riedl</surname><given-names>LA</given-names></name><name><surname>Devireddy</surname><given-names>SR</given-names></name><name><surname>Grondell</surname><given-names>J</given-names></name><name><surname>Connors</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Incidence and implications of idiopathic thrombocytopenia
following transcatheter aortic valve replacement with the Edwards
Sapien((c)) valves: a single center experience</article-title><source>Catheter Cardiovasc Interv</source><year>2014</year><volume>83</volume><issue>4</issue><fpage>633</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">24123706</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitrosz</surname><given-names>M</given-names></name><name><surname>Kazimierczyk</surname><given-names>R</given-names></name><name><surname>Sobkowicz</surname><given-names>B</given-names></name><name><surname>Waszkiewicz</surname><given-names>E</given-names></name><name><surname>Kralisz</surname><given-names>P</given-names></name><name><surname>Frank</surname><given-names>M</given-names></name><etal/></person-group><article-title>The causes of thrombocytopenia after transcatheter aortic valve
implantation</article-title><source>Thromb Res</source><year>2017</year><volume>156</volume><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">28582640</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccardo</surname><given-names>A</given-names></name><name><surname>Rusinaru</surname><given-names>D</given-names></name><name><surname>Petitprez</surname><given-names>B</given-names></name><name><surname>Marticho</surname><given-names>P</given-names></name><name><surname>Vaida</surname><given-names>I</given-names></name><name><surname>Tribouilloy</surname><given-names>C</given-names></name><etal/></person-group><article-title>Thrombocytopenia after aortic valve replacement with freedom solo
bioprosthesis: a propensity study</article-title><source>Ann Thorac Surg</source><year>2010</year><volume>89</volume><issue>5</issue><fpage>1425</fpage><lpage>1430</lpage><pub-id pub-id-type="pmid">20417755</pub-id></element-citation></ref></ref-list></back></article>